Avidity Biosciences, INC Form 4 insider transactions

Avidity Biosciences, Inc. Director Noreen Henig was granted 6,692 restricted stock units and options to purchase 10,034 shares of common stock, aligning her interests with shareholders.

Avidity Biosciences, Inc. Director Carsten Boess was granted 6,692 restricted stock units and 10,034 stock options, aligning his interests with shareholders.

Avidity Biosciences, Inc. Director Edward M. Kaye, MD, was granted 6,692 restricted stock units and options to purchase 10,034 shares of common stock as part of his compensation.

Avidity Biosciences, Inc. Director Arthur A. Levin has acquired 6,692 restricted stock units and 10,034 stock options, signaling continued confidence in the company's future.

Avidity Biosciences, Inc. Director Simona Skerjanec was granted 6,692 restricted stock units and options to purchase 10,034 shares of common stock as part of her compensation.

Avidity Biosciences, Inc. Director Troy Edward Wilson reported the acquisition of 6,692 restricted stock units and 10,034 stock options on June 10, 2025, as part of his compensation.

Avidity Biosciences, Inc. Director Tamar Thompson was granted 6,692 restricted stock units and 10,034 stock options, aligning her interests with the company's long-term performance.

Avidity Biosciences, Inc. director Jean Jinsun Kim was granted 6,692 restricted stock units and 10,034 stock options, aligning her interests with shareholders.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, has filed a Form 4 detailing a pre-planned exercise of stock options and subsequent sale of 20,000 common shares on June 11, 2025, under a Rule 10b5-1 trading plan.

Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, Inc., executed a pre-planned transaction on June 2, 2025, exercising stock options and subsequently selling 5,875 shares of common stock.

Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, exercised stock options and sold shares on May 1, 2025, according to a Form 4 filing with the SEC.

Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Chief Medical Officer Steven George Hughes sold 9,578 shares of Avidity Biosciences stock to cover tax withholding obligations related to vested restricted stock units.

Avidity Biosciences CEO Sarah Boyce sold 31,540 shares of common stock on March 20, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences, sold 11,780 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Michael F. MacLean, CFO of Avidity Biosciences, sold 7,935 shares of common stock on March 20, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, sold 7,778 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences, exercised stock options and sold 20,000 shares of common stock on March 11, 2025, according to a Form 4 filing.

Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Avidity Biosciences director Arthur A. Levin sold 1,872 shares of common stock on January 21, 2025, to cover tax obligations related to vesting of restricted stock units.

Avidity Biosciences' Chief Financial Officer, Michael F. MacLean, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, sold shares to cover tax obligations related to vesting of restricted stock units.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Avidity Biosciences CEO, Sarah Boyce, sold shares to cover tax obligations related to the vesting of restricted stock units.

Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, sold a total of 9,411 shares of common stock in multiple transactions on January 21 and 22, 2025, primarily to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock on January 6, 2025.

Teresa McCarthy, Chief Human Resources Officer at Avidity Biosciences, was granted 50,000 stock options and 25,000 restricted stock units on January 6, 2025.

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, acquired 25,000 restricted stock units and 50,000 stock options on January 6, 2025.